Fig. 2 | Oncogene

Fig. 2

From: The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML

Fig. 2

In vivo potency of BI 894999 and HEXIM1 modulation in AML xenografts. a Kaplan–Meier curve of CIEA-NOG mice intravenously injected with 1 × 107 MV-4-11B AML cells shows prolonged survival of animals daily treated with 2 mg/kg (light blue) or 4 mg/kg (blue) BI 894999 compared to vehicle (gray line). b Tumor volumes of NMRI-nude mice carrying MV-4-11B s.c. xenografts daily treated with either vehicle control (gray), 2 mg/kg (light blue), 4 mg/kg (blue), or 12 mg/kg (dark blue) BI 894999. c Hexim1/HEXIM1 modulation in the blood (red) and tumors (blue) of mice from the respective treatment groups in the experiment shown in Fig. 2b, measured on the indicated days of treatment

Back to article page